Recap: Arrowhead Pharma Q1 Earnings
Portfolio Pulse from Benzinga Insights
Arrowhead Pharma (NASDAQ:ARWR) reported Q1 earnings with an EPS of $-1.24, missing estimates by 51.22% against an expected $-0.82. Revenue decreased by $58.99 million from the same period last year. The company's past earnings performance shows a pattern of missing EPS estimates, leading to significant share price drops the following day.
February 06, 2024 | 9:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arrowhead Pharma reported a significant miss in Q1 earnings and a substantial decrease in revenue compared to last year, continuing a trend of missing EPS estimates.
Given Arrowhead Pharma's history of missing EPS estimates and the subsequent negative impact on its share price, the Q1 earnings miss and revenue decrease are likely to lead to a short-term negative impact on ARWR's stock price. The pattern observed from past earnings suggests that investors react negatively to such misses, potentially leading to a decrease in share price the following day.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100